DRUG · Unmapped registry intervention
Anlotinib Hydrochloride plus Docetaxel
Find medicine records ·
Find other trials using this name
Clinical trial
Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
NCT03750916
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedAnlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Non Small Cell Lung Cancerunresolved
Interventions
Sponsors & collaborators
Qilu Hospital of Shandong Universitylead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.collaborator
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03750916 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.